Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: CIPLA MEDPRO (PTY) LTD., Rosen Heights, Pasita Street, Rosen Park, Bellville, 7530. RSA
BECLATE AQUANASE is indicated for the treatment of the symptoms of seasonal allergic rhinitis, including hay fever.
One metered dose (50 μg) in each nostril, two to four times a day. Alternatively, a dosage of two metered doses (100 μg) into each nostril twice daily can be used. The total daily recommended dose is 200 μg/nostril/day.
BECLATE AQUANASE aqueous nasal spray is for administration through the nasal route only.
The use of large amounts of BECLATE AQUANASE over a short time period may lead to suppression of hypothalamic-pituitary-adrenal (HPA) function. Treatment is symptomatic and supportive.
Symptoms of chronic overdosing include acneform lesions; Cushing’s syndrome (fullness or rounding of face) and menstrual changes.
Withdraw BECLATE AQUANASE gradually to avoid precipitation of acute adrenal insufficiency. Treatment should be symptomatic and supportive
36 months.
BECLATE AQUANASE should be stored at or below 25°C, and should not be refrigerated. Protect from light.
10 ml amber glass vial fitted with a metering atomising pump and nasal adaptor.
Each vial contains 7,5 ml of nasal spray (150 doses).
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
